SLC5A2 and metabolic dysfunction-associated steatotic liver disease: A clinical trial consisting of 156 patients demonstrated that the use of SGLT-2 inhibitors not only enhanced blood glucose control in individuals with NAFLD and T2DM but also significantly reduced visceral fat area and body weight [37].